Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy

OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO

OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more

Significance of gut microbiota in patients receiving CAR T cell immunotherapy

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma

KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma

ESMO President: What to watch for at ESMO 2021

Vaccinations in myeloma patients including for COVID-19

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor

Highlights from ASCO 2021